Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria. - Wikidata - wikimedia - TriplyDB

Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria.

Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria.

http://www.wikidata.org/entity/Q45178530

about

Bypassing vasopressin receptor signaling pathways in nephrogenic diabetes insipidus Sex-specific effects of LiCl treatment on preservation of renal function and extended life-span in murine models of SLE: perspective on insights into the potential basis for survivorship in NZB/W female mice The Trafficking of the Water Channel Aquaporin-2 in Renal Principal Cells-a Potential Target for Pharmacological Intervention in Cardiovascular Diseases Nonsteroidal Anti-Inflammatory Drugs and the Kidney Potential role of purinergic signaling in lithium-induced nephrogenic diabetes insipidus Mice lacking mPGES-1 are resistant to lithium-induced polyuria.GSK3beta mediates renal response to vasopressin by modulating adenylate cyclase activity.alphaENaC-mediated lithium absorption promotes nephrogenic diabetes insipidus.Angiotensin II increases fibronectin and collagen I through the β-catenin-dependent signaling in mouse collecting duct cells Glycogen synthase kinase 3α regulates urine concentrating mechanism in mice.Absence of PKC-alpha attenuates lithium-induced nephrogenic diabetes insipidus.Targeting renal purinergic signalling for the treatment of lithium-induced nephrogenic diabetes insipidus.Specific deletion of glycogen synthase kinase-3β in the renal proximal tubule protects against acute nephrotoxic injury in mice Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: mechanisms for aquaporin 2 down-regulation and cellular proliferation PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.Lithium: a versatile tool for understanding renal physiology.Kidney tubules: intertubular, vascular, and glomerular cross-talk.Telomeres, a busy platform for cell signaling.Physiologic and pathophysiologic roles of cyclooxygenase-2 in the kidney Glycogen synthase kinase-3 regulation of urinary concentrating ability Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice.Rapamycin inhibition of mTORC1 reverses lithium-induced proliferation of renal collecting duct cells.Inhibition of GSK-3β increases trabecular bone volume but not cortical bone volume in adenine-induced uremic mice with severe hyperparathyroidism.Dysregulation of Renal Cyclooxygenase-2 in Rats with Lithium-induced Nephrogenic Diabetes Insipidus.Review of lithium effects on brain and blood.Lithium causes G2 arrest of renal principal cells Lithium induces microcysts and polyuria in adolescent rat kidney independent of cyclooxygenase-2.Role of adenylyl cyclase 6 in the development of lithium-induced nephrogenic diabetes insipidus.Dynamic regulation and dysregulation of the water channel aquaporin-2: a common cause of and promising therapeutic target for water balance disorders.Lithium in the Kidney: Friend and Foe?LISPRO mitigates β-amyloid and associated pathologies in Alzheimer's mice.Lithium-induced NDI: acetazolamide reduces polyuria but does not improve urine concentrating ability.What we need to know about the effect of lithium on the kidney.Molecular mechanisms in lithium-associated renal disease: a systematic review.Physiological insights into novel therapies for nephrogenic diabetes insipidus.Molecular mechanisms regulating aquaporin-2 in kidney collecting duct.Stimulation of UT-A1-mediated transepithelial urea flux in MDCK cells by lithium.Critical role of microsomal prostaglandin E synthase-1 in the hydronephrosis caused by lactational exposure to dioxin in mice.Cooperative mechanisms of acute antidiuretic response to bendroflumethiazide in rats with lithium-induced nephrogenic diabetes insipidus.Tissue injury after lithium treatment in human and rat postnatal kidney involves glycogen synthase kinase-3β-positive epithelium.

P2860

Q24650150-4F0B2C18-E463-4E19-A9CE-C84F46EB9EE9 Q26746146-B523DF1C-71EE-4C86-BAEA-DDC25AF1FE3A Q26768170-878CE657-7775-4F05-B04B-C3641BD79C00 Q28386844-84F78781-F240-4ED9-A27A-87A6B2A72F69 Q28583651-335BD1F7-BB5E-46B5-9050-0BD55D718D9B Q33570060-D4E201EA-086B-4965-9CE5-2D4975773446 Q33702416-096C2ED9-84B5-4F56-AEE6-C20FEED85CFC Q33738668-97639D55-9009-41BF-BDF5-96E40B1B4B86 Q35086481-D7B2C409-81EE-4DF2-8F3B-3DCD9753DC29 Q35178606-3E23ECFC-EBB0-4707-BC38-B56C09B8F330 Q35203675-E99553A6-DD13-48CB-AC9A-08B5FC6658B0 Q35602671-9A1BD9CE-6CFB-4CFE-BB37-6DCAFD79BF04 Q36319741-DA627010-4D19-44D4-889B-8E4B4C1F236B Q36491091-B4B72FE5-6849-4F18-A2BF-CA582433C1AD Q36624751-BFFF854E-79E7-4E33-AA61-E9A256E490AC Q36836247-3250D6B6-E728-4C81-8259-0BF0F1AF7525 Q36837774-5C06E77D-0843-4C70-B2C9-F04099F00061 Q36914679-81C9A31D-99F7-4514-B53B-80F4A944E387 Q37026066-F2430CB7-384B-428B-8826-9777C37DEB33 Q37139392-BB231D1F-1D6C-4461-8697-EC8A7EF3B236 Q37143361-E57D65E1-6357-44DD-9123-5C797656AB25 Q37234738-AC5147B2-D921-4AB4-BA1B-021BEE063EAF Q37418997-3D6C19B7-5442-4B14-B692-6240785D2229 Q37489124-073C0C0E-493C-490A-B1B0-FED33C3D3668 Q37517959-2B8C6648-7442-4775-B8DD-456AEAA64161 Q37604760-BE6E458F-3710-457A-9048-B25DB95A7F46 Q37668476-92C38DEE-6611-4D71-937F-E3F4CA9340D3 Q37730819-B81FABBB-6695-4B8B-8D16-CD4DE4509E15 Q38152961-10A4156C-50EA-41D1-B342-4C53C084F1CA Q38636263-4E486297-EDC9-4A83-BE71-C09CE3AAAC0F Q38724561-9874C4EF-7745-4F62-BA02-107FDD431C5A Q38725462-0E070716-EB18-4BC9-B481-EB96815BA50C Q38819531-033A156B-DEE7-44FA-9BD6-06F52E4D65DC Q38847068-875792C3-57CA-4226-AEAA-BEF14114F08C Q38930238-7AB84B7D-808E-4DC8-B1B3-A59284E1E9E7 Q38985544-56F8F502-6535-4565-8EDC-ADCE94BB2245 Q40028799-B62A2C7F-85DF-462F-A782-0708F7E03BE5 Q42720404-9D43088D-12E5-4432-AD5D-A497C82F51EE Q42777076-B3ECEFD8-B8A1-4A65-A579-67C82BB8344F Q46489396-99D79011-B8CE-4012-B538-661C4869501E

P2860

Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria.

http://www.wikidata.org/entity/Q45178530

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Lithium treatment inhibits ren ...... xygenase 2-dependent polyuria.

@en

Lithium treatment inhibits ren ...... xygenase 2-dependent polyuria.

@nl

type

label

Lithium treatment inhibits ren ...... xygenase 2-dependent polyuria.

@en

Lithium treatment inhibits ren ...... xygenase 2-dependent polyuria.

@nl

prefLabel

Lithium treatment inhibits ren ...... xygenase 2-dependent polyuria.

@en

Lithium treatment inhibits ren ...... xygenase 2-dependent polyuria.

@nl

P1433

Q45178530-6E878CA9-1053-41FB-A96D-E75AE4BE90F5

P1476

Q45178530-334AE7DF-908C-4821-AB5B-24194739C2CE

P2093

Q45178530-28285D05-75D3-4615-8B5C-C6099669D5A4

Q45178530-378BA1EE-2C90-4F2C-93E6-A0D79784D390

Q45178530-A1D686E2-4189-4D5E-84A2-8BBF3AE8C86E

Q45178530-AC860B8F-D160-4B98-BEA8-924D989F5412

Q45178530-DEBB7C4A-A1F1-4A0A-9BE1-9FAEB5F0B4FD

Q45178530-E899D422-74F1-44FD-B7C1-DE4CF096E3A9

Q45178530-F1DF927F-B96A-4E42-80FA-43D02CE6DA74

P2860

Q45178530-04A053EB-0FB1-46D4-875D-01DFC3D7D52A

Q45178530-05FA4335-CE27-4D15-82A7-5A09407160E4

Q45178530-0763FF97-E781-41A0-A2F9-6B0DDE88AE56

Q45178530-0C4ED9FB-FDB8-4EAF-81AA-A9C3515C4C52

Q45178530-1026991D-7800-4546-BCC9-79D048D756D5

Q45178530-13F31F10-2AE2-4AB3-B498-6A2C952D7C9D

Q45178530-1E37A8AE-5A9A-4623-AEDE-A8F88B4A1AAE

Q45178530-21F80F1D-627F-493F-9AAD-AEAE017C2CBE

Q45178530-25A27AEB-B795-4197-9833-2357E48B530D

Q45178530-41C651AF-EC3E-407B-B1C8-F56C6763F96D

P304

Q45178530-8508C040-3057-482B-9E4C-251299903243

P31

Q45178530-F0B8A43C-79C8-42A2-8BC2-E74EEFCA3EA8

P356

Q45178530-490E4D78-02CB-4E68-A827-54E935D9CCD0

P433

Q45178530-A3E127FD-3A6D-4BC1-905B-EC78F87D34A6

P478

Q45178530-6A08E96E-730E-45BE-9F4A-84D879F091E8

P577

Q45178530-27BF21DB-4FB8-4A33-9094-273D60F20616

P698

Q45178530-64F3E44A-DC8C-42A3-B9B8-B5CB00AA96A3

P356

AJPRENAL.00287.2004

P1433

American Journal of Physiology - Renal Physiology

P1476

Lithium treatment inhibits ren ...... xygenase 2-dependent polyuria.

@en

P2093

Chuan-Ming Hao

http://www.w3.org/2001/XMLSchema#string

Hui Cai

http://www.w3.org/2001/XMLSchema#string

Matthew D Breyer

http://www.w3.org/2001/XMLSchema#string

Min Zhao

http://www.w3.org/2001/XMLSchema#string

Ming-Zhi Zhang

http://www.w3.org/2001/XMLSchema#string

Raymond C Harris

http://www.w3.org/2001/XMLSchema#string

Reena Rao

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis

Pathogenesis of nephrogenic diabetes insipidus due to chronic administration of lithium in rats

Involvement of prostaglandin E2, cAMP, and vasopressin in lithium-induced polyuria

Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla

Selective targeting of cyclooxygenase-2 reveals its role in renal medullary interstitial cell survival

Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2

Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5'-flanking regulatory sequences.

Lithium inhibits glycogen synthase kinase-3 by competition for magnesium.

Membrane-associated PGE synthase-1 (mPGES-1) is coexpressed with both COX-1 and COX-2 in the kidney.

Prostaglandin E receptors and the kidney.

P304

F642-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPRENAL.00287.2004

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

288

http://www.w3.org/2001/XMLSchema#string

P577

2004-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15585669

http://www.w3.org/2001/XMLSchema#string